1. α-Enolase Lies Downstream of mTOR/HIF1α and Promotes Thyroid Carcinoma Progression by Regulating CST1
   Yang Liu et al, 2021, Frontiers in Cell and Developmental Biology CrossRef
2. Dynamic analysis of immune status in patients with intracranial germ cell tumor and establishment of an immune risk prognostic model
   Hairong Wang et al, 2022, Frontiers in Immunology CrossRef
3. Association of Enolase-1 with Prognosis and Immune Infiltration in Breast Cancer by Clinical Stage
   Yue-Yu Shi et al, 2023, Journal of Inflammation Research CrossRef
4. Phase 1 trial of 4-1BB-based adoptive T-cell therapy targeting human telomerase reverse transcriptase in patients with advanced refractory solid tumors
   Wonyoung Choi et al, 2023, Cytotherapy CrossRef
5. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study
   Diana Cortes-Selva et al, 2024, Blood CrossRef
6. Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype
   Simone Borgoni et al, 2018, OncoImmunology CrossRef
7. Role of diet and gut microbiota on colorectal cancer immunomodulation
   Carolina Vieira De Almeida et al, 2018, World Journal of Gastroenterology CrossRef
8. Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer
   Eda K. Holl et al, 2019, Frontiers in Immunology CrossRef
9. Enolase 1 Correlated With Cancer Progression and Immune-Infiltrating in Multiple Cancer Types: A Pan-Cancer Analysis
   Wenhua Xu et al, 2021, Frontiers in Oncology CrossRef
10. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma
    Jie Sun et al, 2017, Oncology Reports CrossRef
11. In pancreatic cancer patients, chemotherapy reshapes the gene expression profile and antigen receptor repertoire of T lymphocytes and enhances their effector response to tumor-associated antigens
    Silvia Brugiapaglia et al, 2024, Frontiers in Immunology CrossRef
12. Impact of microbiota-immunity axis in pancreatic cancer management
    Ilenia Bartolini et al, 2022, World Journal of Gastroenterology CrossRef
13. Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners
    Paola Cappello et al, 2018, Cancers CrossRef
14. Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19–9 level as a prognostic factor in patients with resected pancreatic cancer
    Teruhisa Sakamoto et al, 2019, Hepatobiliary & Pancreatic Diseases International CrossRef
15. The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer
    Claudia Curcio et al, 2021, Molecules CrossRef
16. The Janus-Faced Role of Cell-Mediated Immune Responses in Pancreatic Cancer
    Elena Niccolai et al, 2017, EMJ Oncology CrossRef
17. Circulating autoantibodies to alpha-enolase (ENO1) and far upstream element-binding protein 1 (FUBP1) are negative prognostic factors for pancreatic cancer patient survival
    Claudia Curcio et al, 2023, Clinical and Experimental Medicine CrossRef
18. Role of microbiome in cancer immunotherapy
    Edda Russo et al, 2022, Cancer Immunology and Immunotherapy CrossRef
19. Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer
    Xiaoling Qian et al, 2017, Oncotarget CrossRef